Skip to content
Home/Companies/Biotech/Callio Therapeutics

Callio Therapeutics

Biotech·France·Active·1yr hold
Entry
2025
Hold
1yr
Status
Active

Who owns Callio Therapeutics?

Callio Therapeutics is a French Biotech company, currently owned by Jeito Capital since 2025.

Hand-verified · updated 2026-09-30

Open JSON · CC-BY
Jeito Capital
Investor
Jeito Capital
Jeito II · 2026 · VC

Key facts

HQFrance
SectorBiotech

More from Jeito II

Other portfolio companies in the same fund.

Adcendo
Adcendo
Active
BiotechDenmark· 2026
Alveus Therapeutics
Alveus Therapeutics
Active
BiotechUS· 2026
Bionyra Pharma
Active
BiotechFrance· 2026
Augustine Therapeutics
Augustine Therapeutics
Active
BiotechBelgium· 2025
Azafaros
Azafaros
Active
BiotechNetherlands· 2025
Odyssey Therapeutics
Exited 2026
BiotechUS· 2025

More PE-backed in Biotech

Comparable biotech deals from other GPs.

Abbisko Healthcare
Active
The Carlyle GroupChina
Adagene
Active
General AtlanticChina
Advanced Cell Diagnostics
Active
Summit PartnersUS
Akero Therapeutics
Akero Therapeutics
Active
General AtlanticUS
Aldevron
Aldevron
Active
TA AssociatesUS
Alloy Therapeutics
Alloy Therapeutics
Active
Mubadala CapitalUS

Questions

Who owns Callio Therapeutics?

Callio Therapeutics is currently owned by Jeito Capital, through Jeito II, since 2025.

When did Jeito Capital acquire Callio Therapeutics?

Jeito Capital acquired Callio Therapeutics in 2025.

Look up another firm or company
Data refreshed weekly · Sourced from public filings · Report an issue